GSK: Heart Drug Darapladib Fails Trial Again

GSK: Heart Drug Darapladib Fails Trial Again
share Share
GlaxoSmithKline has announced that its innovative heart drug darapladib has failed reduce heart attacks or other major cardiac events in patients suffering acute coronary syndrome.

This marks a further disappointment for the heart medicine that has previously failed to pass a late-stage trial for patients with well-treated heart disease. 

GSK’s President of Pharmaceuticals R&D Patrick Vallance expressed his disappointment with the result of the second phase III study that did not support a regulatory submission.

The company’s statement declared that the drug darapladib did not achieve the desired primary endpoint of a reduction of major coronary events versus placebo when added to standard of care.


13 May 2014

«« Cardiac Hypertrophy: Preventable via Protein


Heart Rhythm 2014: ZOLL Showcase to Include LifeVest Wearable Defibrillator »»

Published on : Tue, 13 May 2014



Related Articles

Women looking to lower their chances of developing cardiovascular disease have heard it before: maintain a healthy weight, keep... Read more

The world's first leadless pacemaker has demonstrated promising results as per a study conducted by Vivek Reddy,... Read more

Late breaking trial session at ESC Heart Failure Congress shows significant benefits for various device populations with the... Read more

Heart, heart attack, heart disease, GSK, acute coronary syndrome, drug trails GlaxoSmithKline has announced that its innovative heart drug darapladib has failed reduce heart attacks or other major cardiac events in patients suffering...

No comment


Please login to leave a comment...

Highlighted Products